Table 1 Demographics and baseline characteristics of 65 patients admitted to the 5th Medical Center of PLA General Hospital (Jan 20–Feb 23, 2020) with COVID-19 in different clinical types.
Variables | Total (n = 65) | Mild (n = 10) | General (n = 32) | Severe (n = 8) | Critical (n = 15) | P | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | ||
Age, years | |||||||||||
≤ 65 | 50 | 76.92 | 10 | 10.00 | 29 | 90.63 | 5 | 62.50 | 6 | 40.00 | |
> 65 | 15 | 23.08 | 0 | 0.00 | 3 | 9.38 | 3 | 37.50 | 9 | 60.00 | 0.0003 |
Sex | |||||||||||
Male | 36 | 55.38 | 6 | 60.00 | 18 | 56.25 | 4 | 50.00 | 8 | 53.33 | |
Female | 29 | 44.62 | 4 | 40.00 | 14 | 43.75 | 4 | 50.00 | 7 | 46.67 | 1 |
Exposure history | |||||||||||
No exposure history | 7 | 10.77 | 0 | 0.00 | 1 | 3.13 | 0 | 0.00 | 6 | 40.00 | |
Recently been to Wuhan | 36 | 55.38 | 8 | 80.00 | 20 | 62.50 | 3 | 37.50 | 5 | 33.33 | |
Contacted with patients with COVID-19 | 17 | 26.15 | 0 | 0.00 | 10 | 31.25 | 5 | 62.50 | 2 | 13.33 | |
Contacted with people from Wuhan | 5 | 7.69 | 2 | 20.00 | 1 | 3.13 | 0 | 0.00 | 2 | 13.33 | 0.0006 |
With at least one underlying disease | 22 | 33.85 | 1 | 10.00 | 8 | 25.00 | 4 | 50.00 | 9 | 60.00 | 0.0264 |
Treatment | |||||||||||
Respiratory support | |||||||||||
Oxygen therapy | 14 | 21.54 | 0 | 0.00 | 14 | 43.75 | 0 | 0.00 | 0 | 0.00 | |
HFNC | 8 | 12.31 | 0 | 0.00 | 0 | 0.00 | 8 | 100.00 | 0 | 0.00 | |
NIPPV | 12 | 18.46 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 12 | 80.00 | |
IPPV | 3 | 4.62 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 20.00 | < 0.0001 |
CRRT | 3 | 4.62 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 20.00 | 0.0078 |
Glucocorticoids | 31 | 47.69 | 0 | 0.00 | 10 | 31.25 | 8 | 100.00 | 13 | 86.67 | < 0.0001 |
Prognosis | |||||||||||
Remained in hospital | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | |
Discharged | 63 | 96.92 | 10 | 100.00 | 32 | 100.00 | 8 | 100.00 | 13 | 86.67 | |
Died | 2 | 3.08 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 13.33 | 0.124 |
Med | IQR | Med | IQR | Med | IQR | Med | IQR | Med | IQR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Onset of symptom to laboratory confirmed, days | 5 | 3–7 | 3 | 1–9 | 3.5 | 2.5–6 | 5.5 | 2.5–9 | 7 | 4–14 | 0.0004 |
Onset of symptom to pneumonia, days | 6 | 3–8 | 4 | 4–9 | 5.5 | 2–7.5 | 5 | 2.5–7 | 7 | 5–11 | 0.0443 |
Onset of symptom to virus RNA clearance, days | 15 | 11–20 | 6 | 4–12 | 14.5 | 11.5–18.5 | 18 | 13–22 | 20 | 16–26 | 0.0001 |
Methylprednisolone time (n = 31) | 7 | 5–9 | – | – | 5.5 | 4–9 | 7.5 | 5–10.5 | 8 | 6.5–10 | 0.322 |
Onset of symptom to discharge, days (n = 63) | 27 | 17–34 | 13 | 9–18 | 24.5 | 16–32 | 35 | 31–44.5 | 34 | 28–41 | < 0.0001 |
